Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop

Fig. 6

circEXOC6B enhances the sensitivity of CRC cells to 5-FU. A TUNEL showed that knockdown of circEXOC6B expression reduced the 5-FU-induced apoptosis of CRC cells, whereas overexpression of circEXOC6B made CRC cells more sensitive to 5-FU treatment. Scale: 50 μm. B Western blot results showed that knockdown or overexpression of circEXOC6B affected the expression of apoptotic markers in CRC cells after 5-FU treatment. C CCK8 revealed that downregulation of circEXOC6B antagonized the inhibitory role of 5-FU in CRC cell proliferation. In contrast, upregulation of circEXOC6B enhanced the effect of 5-FU on proliferation. D Gross image of subcutaneous tumors. E The tumor volume in the sh-circEXOC6B group showed no difference from the untreated group, whereas the tumor size was significantly decreased in the sh-NC group after 5-FU treatment. F IHC demonstrated that the apoptotic marker cleaved-caspase3 was not increased in the sh-circEXOC6B group but was dramatically elevated in the sh-NC group after 5-FU treatment. Scale: 20 μm. G TUNEL showed that the apoptosis in the sh-circEXOC6B group was unchanged with 5-FU treatment, whereas it was remarkably increased in the sh-NC group after 5-FU treatment. Scale: 50 μm

Back to article page

Molecular Cancer

ISSN: 1476-4598